RxDoctor Payments Data

Cynthia Baer

Nurse Practitioner · Fresno, CANPI 1770564270

Payments from drug & device makers

$20,637in general payments, 2019–2025

Across 909 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Boehringer Ingelheim$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$20,619100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie141$3,108
Boehringer Ingelheim112$1,768
Amgen60$1,468
Novo Nordisk68$1,397
Lilly USA, LLC82$1,241
AstraZeneca16$1,206
Bayer25$831
Pfizer47$784
Esperion Therapeutics, Inc.33$728
GSK40$711
Otsuka America Pharmaceutical, Inc.26$494
Biohaven Pharmaceuticals, Inc.15$445
Johnson & Johnson13$379
Novartis25$355
Axsome Therapeutics, Inc.9$337
Abiomed7$331
Abbott9$322
Dynavax Technologies Corporation9$302
Viiv Healthcare Company7$247
Madrigal Pharmaceuticals2$245
E.r. Squibb & Sons, L.L.C.3$244
Boston Scientific5$229
Takeda Pharmaceuticals U.S.A., Inc.19$224
Biohaven Pharmaceutical Holding Company Ltd.11$215
Antares Pharma, Inc.4$206
Daiichi Sankyo Inc.9$202
Phathom Pharmaceuticals, Inc.5$179
Sanofi-aventis U.S. LLC4$174
SK Life Science, Inc.5$158
Exact Sciences7$155
Lundbeck LLC8$152
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$149
Gilead2$125
Merck7$122
Corcept Therapeutics1$100
Radius Health, Inc.4$98
Neurelis, Inc.1$95
Sumitomo Pharma America, Inc.5$89
Aimmune Therapeutics, Inc.5$86
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$82
Teva Pharmaceuticals USA, Inc.4$80
Halozyme Inc3$74
Astellas Pharma US Inc4$73
Nestle Healthcare Nutrition Inc.3$61
Xeris Pharmaceuticals, Inc.3$61
Dexcom, Inc.3$55
Amarin Pharma, Inc.2$41
Otsuka Pharmaceutical Development & Commercialization, Inc.2$38
Verity Pharmaceuticals Inc.2$35
Scilex Pharmaceuticals Inc.2$35
Medtronic2$34
Hologic Sales And Service, LLC2$31
Mylan Specialty L.p.2$29
Almatica Pharma LLC1$25
Recordati_rare_diseases_inc.1$25
Vertex1$23
Ferring Pharmaceuticals Inc.1$22
Inspire Medical Systems, Inc.1$20
Coloplast1$18
Kowa Pharmaceuticals America, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,637 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$223,838
Medicare patients
399
Services billed
4,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$208,090
JardianceEmpagliflozin123$189,880
FarxigaDapagliflozin Propanediol91$105,575
TrulicityDulaglutide53$104,299
Repatha SureclickEvolocumab55$58,457
EliquisApixaban55$44,279
XareltoRivaroxaban26$40,835
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$35,625
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$27,903
MyrbetriqMirabegron14$17,395
LinzessLinaclotide13$15,112
Nurtec OdtRimegepant Sulfate13$14,890
Breo ElliptaFluticasone/Vilanterol16$14,774
Atorvastatin Calcium825$10,092
Ezetimibe291$8,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,397$208,090107 claims
Boehringer IngelheimJardiance$1,768$189,880123 claims
AstraZenecaFarxiga, Symbicort$1,206$109,979105 claims
Lilly USA, LLCTrulicity$1,241$104,29953 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$711$78,30264 claims
PfizerEliquis, Nurtec Odt$784$59,16968 claims
Johnson & JohnsonXarelto$379$40,83526 claims
AbbVieLinzess, Synthroid$3,108$17,41643 claims
Astellas Pharma US IncMyrbetriq$73$17,39514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →